Aller au contenu

Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results.

Nom du journal : Leukemia

Année : 2023

Volume : 37

Page de départ : 1048-1059

Auteurs: Mauro, MJ, Hughes, TP, Kim, DW, Rea, D, Cortes, JE, Hochhaus, A & al,